Table 2.
Numbers of potential inclusions (individual diagnoses), with Cancer Registry linkage, and exclusions, to give final sample sizes by cancer site. The final sample is described in terms of size (N), age (mean, SD), number (%) who are male, and number (%) with an index cancer feature introduced during guidance revision.
| Cancer site | Potential inclusions | No. (%) with NCRS linkage | Exclusions | Final sample |
|||
|---|---|---|---|---|---|---|---|
| N | Age, mean (SD) | No. (%) male | No. (%) in New-NICE group | ||||
| Bladder | 9030 | 2583 (28·6) | 3787 | 5243 | 73·0 (11·5) | 3870 (73·8) | 799 (15·2) |
| Breast | 37,369 | 17,452 (46·7) | 21,827 | 15,542 | 62·9 (16·7) | 0 (0) | 858 (5·5) |
| Colorectal | 25,011 | 11,786 (47·1) | 13,169 | 11,842 | 70·2 (12·6) | 6477 (54·7) | 5017 (42·4) |
| Lung | 20,033 | 9080 (45·3) | 6926 | 13,107 | 71·9 (10·6) | 7175 (54·7) | 3384 (25·8) |
| Myeloma | 2758 | 1257 (45·6) | 1224 | 1534 | 71·0 (11·5) | 818 (53·3) | 1529 (99·7) |
| Oesophagus | 6041 | 2710 (44·9) | 1769 | 4272 | 71·3 (11·8) | 2900 (67·9) | 451 (10·6) |
| Ovary | 3887 | 1672 (43·0) | 1406 | 2481 | 65·5 (13·8) | 0 (0) | 614 (24·7) |
| Pancreas | 4844 | 2292 (47·3) | 1677 | 3167 | 71·7 (11·5) | 1580 (49·9) | 2672 (84·4) |
| Prostate | 30,083 | 14,488 (48·2) | 8630 | 21,453 | 71·6 (9·3) | 21,453 (100) | 1662 (7·7) |
| Stomach | 3839 | 1930 (50·3) | 1051 | 2788 | 73·4 (12·2) | 1823 (65·4) | 294 (10·5) |
| Uterus | 4382 | 2124 (48·5) | 1876 | 2506 | 67·1 (11·3) | 0 (0) | 713 (28·5) |
| Total | 147,277a | 67,374 (45·7) | 63,342b | 83,935 | 69·6 (12·8) | 46,096 (54·9) | 17,993 (21·4) |
a
147,277 cancers in 147,106 participants (of whom 317 had multiple index cancers, including cancer types not in this study).
b
63,342 exclusions in 63,171 patients.